Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2 (PePS2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02733159|
Recruitment Status : Active, not recruiting
First Posted : April 11, 2016
Last Update Posted : April 16, 2019
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Non-Small-Cell Lung||Drug: pembrolizumab||Phase 2|
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. There are several studies which demonstrate a role for the immune system in fighting lung cancer. However, there are multiple mechanisms by which cancer dampens this response. The PD-1 receptor-ligand interaction is one of the major pathways hijacked by tumours to help evade detection and elimination by the cells of the immune system. A number of compounds which block this pathway, including the drug pembrolizumab, have shown impressive results in some patients.
At present all of the trials with pembrolizumab reported thus far have been in patients with a good Performance Status of 0-1, a measure of daily activity. Unfortunately many patients with lung cancer have impaired performance status, making them ineligible for trials of new therapies including anti PD-1. Clinical trials of standard-of-care therapy have been successfully performed in the PS=2 only population demonstrating the feasibility of performing clinical trials in this population.
In this trial, the investigators would like to determine whether this drug can be used to treat Performance status 2 patients with a lower general daily activity. The purpose of this trial is to determine that pembrolizumab is safe and tolerable. The investigators would also like to see how well the treatment works, find out more information about tumour shrinkage, and learn more about the disease and how it changes over time.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||62 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2|
|Actual Study Start Date :||November 7, 2016|
|Estimated Primary Completion Date :||February 2020|
|Estimated Study Completion Date :||February 2020|
Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
Other Name: MK-3475
- Toxicity - Treatment Related Dose Delay or Treatment Discontinuation [ Time Frame: Through study completion, a maximum of 2 years and 6 months after end of treatment ]Adverse events will be recorded in relation to each cycle of treatment and graded according to CTCAE criteria. The toxicity co-primary outcome measure for the trial is defined as the occurrence of a treatment-related dose delay or treatment discontinuation due to toxicity.
- Efficacy - Durable Clinical Benefit [ Time Frame: ≥18 weeks, up to maximum of 2 years ]Patients will have CT scans every 9 weeks from baseline until disease progression. On each occasion, overall tumour burden will be assessed using RECIST version 1.1. The efficacy co-primary outcome measure for the trial is durable clinical benefit defined as the occurrence of CR, PR or SD without prior progressive disease at or after the second scheduled CT scan (scheduled to occur at 18 weeks).
- Objective Response [ Time Frame: ≥18 weeks, up to maximum of 2 years ]Objective response (OR) is the occurrence of CR or PR as the best overall response. OR will be based on responses confirmed using the subsequent 9-weekly scan but OR based on unconfirmed responses will also be reported.
- Health Related Quality of Life [ Time Frame: Through study completion, up to a maximum of 2 years ]This is defined as the functional effect of a medical condition and/or its consequent treatment upon a patient. The purpose of Health Related Quality of Life (HRQoL) measurement is to quantify the degree to which the medical condition or its treatment impacts the individual's life in a valid and reproducible way. HRQoL will be assessed over time using FACT-L questionnaire and EQ-5D questionnaire.
- Time to Progression [ Time Frame: Time to progression up to 2 years ]This is defined as the time from commencement of trial treatment to the date of CT scan when progressive disease first recorded. Patients with no recorded progression at the time of analysis or who die without recorded progression will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression.
- Progression-free Survival Time [ Time Frame: Progression-free survival time up to 2 years ]This is defined as the time from commencement of trial treatment to the date of CT scan when progressive disease first recorded or date of death without previously recorded progression. Patients who are alive with no recorded progression at the time of analysis will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression.
- Overall Survival Time [ Time Frame: Survival time up to 2 years or date of death ]This is defined as the time from commencement of trial treatment to the date of death. Patients who are alive at the time of analysis will be censored at the date last seen alive.
- Duration of Objective Response and Duration of Stable Disease [ Time Frame: Survival time up to 2 years or date of death ]This is defined as the time from commencement of trial treatment to the date of the subsequent CT scan when progressive disease is first confirmed or date of death without previously recorded progression. This outcome is calculated and reported separately for patients who acheive an OR or SD. Patients experiencing OR or SD who are alive with no recorded progression at the time of analysis will be censored at the date of the CT scan when they were last recorded with an evaluable measure that was not progression.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02733159
|The Christie NHS Foundation Trust|
|Manchester, Greater Manchester, United Kingdom, M20 4BX|
|Southampton University Hospitals NHS Trust|
|Southampton, Hampshire, United Kingdom, SO16 6YD|
|Maidstone and Tunbridge Wells NHS Trust|
|Maidstone, Kent, United Kingdom, ME16 9QQ|
|University Hospital Birmingham NHS Foundation Trust|
|Birmingham, West Midlands, United Kingdom, B15 2TH|
|Velindre Cancer Centre|
|Cardiff, United Kingdom, CF14 2TL|
|Western General Hospital|
|Edinburgh, United Kingdom|
|United Lincolnshire Hospitals NHS Trust|
|Lincoln, United Kingdom, LN2 5QY|
|Barts Health NHS Trust|
|London, United Kingdom, E1 1BB|
|University College London Hospitals|
|London, United Kingdom, NW1 2BU|
|The Royal Marsden Hospital|
|London, United Kingdom, SW3 6JJ|
|Principal Investigator:||Gary Middleton, Professor||University of Birmingham|